Edition:
United Kingdom

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

21.73USD
10 Dec 2018
Change (% chg)

$0.49 (+2.31%)
Prev Close
$21.24
Open
$21.24
Day's High
$22.47
Day's Low
$21.12
Volume
1,135,437
Avg. Vol
634,617
52-wk High
$69.02
52-wk Low
$11.50

Latest Key Developments (Source: Significant Developments)

Clovis says Positive Outcome In European Opposition Proceeding Related To Rubraca
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES POSITIVE OUTCOME IN EUROPEAN OPPOSITION PROCEEDING RELATED TO RUBRACA®.CLOVIS ONCOLOGY INC - CLAIMS DIRECTED TO RUBRACA( )CRYSTALLINE FORMS UPHELD.CLOVIS ONCOLOGY INC - PATENT PROTECTION FOR RUBRACA IN EUROPE CONFIRMED UNTIL AT LEAST 2031.CLOVIS - RUBRACA COMMERCIAL FORM ENTITLED TO EUROPEAN REGULATORY EXCLUSIVITY UNTIL AT LEAST 2028 (2029 IF INDICATION IN SECOND TUMOR TYPE IS APPROVED).  Full Article

Clovis Oncology Reports Q2 Loss Per Share $1.94
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES SECOND QUARTER 2018 OPERATING RESULTS.Q2 ADJUSTED LOSS PER SHARE $1.55 EXCLUDING ITEMS.Q2 LOSS PER SHARE $1.94.Q2 EARNINGS PER SHARE VIEW $-1.88 -- THOMSON REUTERS I/B/E/S.QUARTERLY PRODUCT REVENUE, NET $23.76 MILLION VERSUS $14.62 MILLION.  Full Article

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer
Monday, 4 Jun 2018 

June 4 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY SUBMITS APPLICATION TO EMA TO EXPAND USE OF RUBRACA®▼ (RUCAPARIB) TO INCLUDE MAINTENANCE TREATMENT FOR WOMEN WITH RECURRENT OVARIAN CANCER.CLOVIS ONCOLOGY - SUBMISSION BASED ON POSITIVE PHASE 3 ARIEL3 CLINICAL TRIAL.CLOVIS ONCOLOGY INC - SAFETY FINDINGS FROM ARIEL3 TRIAL WERE CONSISTENT WITH PREVIOUS CLINICAL TRIALS.CLOVIS ONCOLOGY INC - ANTICIPATES OPINION FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE REGARDING EXPANDED USE OF RUBRACA BY END OF 2018.  Full Article

Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock
Tuesday, 17 Apr 2018 

April 16 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK.CLOVIS ONCOLOGY INC- PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.25% CONVERTIBLE SENIOR NOTES DUE 2025.CLOVIS ONCOLOGY- ANNOUNCED PRICING OF 1.8 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT A PRICE TO PUBLIC OF $54.41 PER SHARE.CLOVIS ONCOLOGY INC - PRICED $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES AT PRICE TO PUBLIC OF 100% OF PRINCIPAL AMOUNT OF NOTES.  Full Article

Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock
Monday, 16 Apr 2018 

April 16 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer
Friday, 6 Apr 2018 

April 6 (Reuters) - Clovis Oncology Inc ::RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER.U.S. FDA APPROVED RUBRACA TABLETS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CERTAIN TYPES OF RECURRENT CANCER.IN ADDITION TO GRANTING RUBRACA APPROVAL FDA CONVERTED APPROVAL OF INITIAL TREATMENT INDICATION FROM ACCELERATED TO REGULAR APPROVAL.  Full Article

Clovis Oncology reports Q3 adjusted shr loss of $1.24
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Clovis Oncology Inc -:CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS.Q3 ADJUSTED LOSS PER SHARE $1.24 EXCLUDING ITEMS.Q3 LOSS PER SHARE $1.24.Q3 EARNINGS PER SHARE VIEW $-1.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Photo

GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

LONDON GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion (4 billion pounds), a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma Walmsley that unnerved investors. | Video